Uncontrolled diabetes mellitus and hyperglucagonemia associated with an islet cell carcinoma.
A 53 year old woman presented with diabetes mellitus, hyperglucagonemia (600 to 1,500 pg/ml), clinical hyperparathyroidism and an abdominal mass diagnosed on biopsy as an islet cell carcinoma. Glucagon content of the tumor was 0.78 mug/g wet weight. Hourly blood samples during a 24 hour period revealed a direct correlation between plasma glucose and glucagon. The oral administration of glucose paradoxically increased whereas the intravenous administration decreased plasma glucagon. Circulating glucagon levels were markedly increased with arginine and epinephrine infusion. Both short- and long-term administration of alpha adrenergic blockade depressed the glucagon response to epinephrine infusion. In contrast, long-term alpha adrenergic blockade increased glucagon secretion despite improved glucose tolerance during a second 24 hour study. Although the patient demonstrated overt clinical and chemical findings of hyperparathyroidism, parathyroid hormone (PTH) was not detected in her plasma. The pattern of tumor growth was consistent with an origin from pancreatic islets. We conclude that (1) the tumor was responsive to physiologic stimuli known to affect glucagon secretion; (2) elevations of plasma glucagon levels with oral and dietary glucose suggest regulation of secretion by intestinal factors; and (3) improvement of glucose tolerance with alpha adrenergic blockade may be related to increased insulin secretion.
D007516:Adenoma, Islet Cell / Q000097:blood / Q000150:complications* / Q000473:pathology; D001120:Arginine / Q000494:pharmacology; D001786:Blood Glucose / Q000032:analysis; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D005934:Glucagon / Q000097:blood* / Q000276:immunology; D005947:Glucose / Q000008:administration & dosage / Q000494:pharmacology; D005951:Glucose Tolerance Test; D005954:Glucosephosphate Dehydrogenase / Q000378:metabolism; D006593:Hexokinase / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood / Q000150:complications* / Q000473:pathology; D010643:Phenoxybenzamine; D013194:Staining and Labeling
D001786:Blood Glucose; D007328:Insulin; D010643:Phenoxybenzamine; D005934:Glucagon; D001120:Arginine; D005954:Glucosephosphate Dehydrogenase; D006593:Hexokinase; D005947:Glucose; D004837:Epinephrine